 |
|
|
| |
Clinical Characteristics of Patients Who Developed HCC While Receiving Tenofovir Disoproxil Fumarate (TDF) Up to 336 Weeks of Therapy
|
| |
| |
Reported by Jules Levin
APASL June 6-10 2013 Singapore
W. Ray Kim1, Rohit Loomba2, Selim Gurel3, John Flaherty4, Eduardo B. Martins4, Leland J. Yee4, Phillip Dinh4, Maria Buti5, Patrick Marcellin6
1Mayo Clinic, Rochester, MN, USA; 2University of California at San Diego, San Diego, CA, USA; 3University of Uludag, Bursa, Turkey;
4Gilead Sciences, Inc., Foster City, CA, USA; 5Hospital General Universitari Vall d'Hebron, Barcelona, Spain; 6Hôpital Beaujon, University of Paris, Clichy, France
4. KimWR, et al. EASL 2013, abstract 43
EASL: Long-term Tenofovir Disoproxil Fumarate (TDF) Therapy and the Risk of Hepatocellular Carcinoma - (05/08/13)
EASL: HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBE-) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HEPNET.GREECE COHORT STUDY - (05/08/13)
EASL: Liver Disease in HBV-HIV Coinfection- Significant Fibrosis is Present Despite HBV Suppression and Anti-Retroviral Therapy - (05/15/13)
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection - (05/13/13)
EASL: 5-year Entecavir treatment in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics - (05/15/13)
|
| |
|
|
|
|
|
